Cerebrolysin CAS 12656-61-0 High Quality Neurotrophic Peptide API Pharmaceutical Raw Material with COA and HPLC Test Repo

Cerebrolysin More Info

Cerebrolysin, identified by the Chemical Abstracts Service Registry Number 12656-61-0, is a peptide-based neuroprotective drug derived from purified porcine brain proteins through a standardized enzymatic process. The resulting aqueous solution contains a complex mixture of low-molecular-weight peptides and free amino acids, with approximately eighty-five percent of th content present as free amino acids and fifteen percent as peptides bound in chains. This extract includes twenty-four essential and non-essential amino acids along with smaller peptides that mimic the actions of endogenous neurotrophic factors, enabling the preparation to cross the blood-brain barrier more effectively than larger protein-based therapeutics.

The pharmacological mechanisms of Cerebrolysin are multimodal, reflecting its complex composition of neurotrophic peptide fragments. Preclinical studies have demonstrated that the drug reduces amyloid-beta deposition and tau protein in models of dementia, while also enhancing synaptic density and promoting neurogenesis in the dentate gyrus of the hippocampus. In stroke models, Cerebrolysin has been shown to stabilize cellular structural integrity through calpain inhibition, reduce the number of apoptotic cells following ischemic lesions, and promote neurogenesis in the subventricular zone, thereby supporting the brain's intrinsic self-repair capacity. Electrophysiological research has revealed that components of Cerebrolysin act as presynaptic GABAB receptor agonists, inhibiting excessive excitatory neurotransmitter release that would otherwise contribute to excitotoxic neuronal injury. Additionally, the preparation contains peptides that potentiate GABAA receptor responses, further contributing to its neuroregulatory effects.

The clinical applications of Cerebrolysin are primarily focused on acute and chronic neurological conditions, though its regulatory approval varies substantially across different regions. The drug is currently approved for clinical use in more than fifty countries, including Austria, Germany, Poland, Romania, South Korea, Mexico, Vietnam, and Ukraine, where it is indicated as an adjunctive treatment for ischemic stroke, traumatic brain injury, and dementia syndromes including Alzheimer's disease. Notably, Cerebrolysin has received recognition in the Canadian INCOG guidelines for traumatic brain injury management, receiving a level 1b recommendation for improving attentional function in patients with moderate to severe TBI. Recent clinical research presented at the World Stroke Congress in October 2024 demonstrated that Cerebrolysin combined with speech therapy significantly improved language function in patients with post-stroke aphasia compared to speech therapy alone, with treatment effects becoming progressively larger at thirty, sixty, and ninety days following the intervention.

The safety and tolerability profile of Cerebrolysin has been characterized through decades of clinical use and post-marketing surveillance studies. The European Medicines Agency classifies the drug as belonging to the SAFE category, with reported adverse drug reactions generally being transient and mild in intensity. The most commonly observed side effects include transient dizziness, headache, gastrointestinal disturbances such as nausea and diarrhea, and site reactions including irritation or burning sensation. However, several contraindications require careful patient selection: the drug is contraindicated in individuals with epilepsy due to the potential for increased seizure frequency, in patients with severe renal impairment, and in those with known hypersensitivity to any component of the formulation. Rare but serious hypersensitivity reactions, including anaphylaxis, have been documented in case reports, underscoring the importance of appropriate medical supervision during administration.

The regulatory landscape surrounding Cerebrolysin is notable for its geographic limitations and the ongoing debate regarding the strength of clinical evidence supporting its use. Despite being widely available in many countries across Asia, Eastern Europe, and Latin America, Cerebrolysin is not approved for use in the United States by the Food and Drug Administration, nor has it received marketing authorization from the European Medicines Agency for most European Union member states. A Cochrane review of six randomized controlled trials involving nearly six hundred participants found only minimal improvements in cognitive assessment scales, and the published literature contains inconsistent results, with some studies suggesting limited clinical relevance compared to placebo. Researchers have called for larger, multinational controlled trials to confirm the therapeutic utility of Cerebrolysin across various neurological conditions and to better define its role in clinical practice, particularly given the promising preclinical evidence and the need for effective neuroprotective therapies.

Package Image

FAQ

Q1. Can I get a free sample?

We can send you a samll free sample, and you only need to pay for the shipping cost.

Q2. What is the HyperChem payment term?

T/T in advance
LC at sight
DP at sight

Bank transfer

PayPal

Bitcoin...

Q3. What is HyperChem shipment policy?

Our policy is to strive for the quickest shipment time possible.

For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.

Q4. What is HyperChem shipment term?

By Express  
FedEx  UPS  DHL  EMS                               
Fast: 3-7 days around, high cost, door to door service

By Air                                        
Suitable for more than 50kg 
Fast: 3-7 days, hight cost, port to port, professional broker needed 

By Sea
Suitable for more than 500kg      
Fast: 7-45 days, low cost, port to port, professional broker needed 

We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. What HyperChem will provide after shipment?

For sample orders: 
After shipment is done, an timely email including:

1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice

For commercial orders
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.

Company Profile

Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to cater to the requirements of our diverse range of clients.

Among them, our key client industrial sectors around the global are:

Pharmaceuticals
Nutrition Ingredients/ Dietary supplements
Cosmetic Ingredients
Food Ingredients
Veterinary API
Agriculture fertilizer
Custom Synthesis lab supply

HyperChem provides to its wonderful and honorable clients comprehensive purchasing and distribution services which ensure that we are delivering the right generic, raw, or customized product, make sure that we are delivering it at the right time, ensure that it is delivered in the specified amount, and in the right kind of packaging to clients and customers of all types of industries irrespective of their size of operation.